Thermo Fisher scraps $11.5bn Qiagen deal after failed tender offer
Thermo Fisher Scientific has scrapped its previously planned $11.5 billion acquisition of Qiagen after its offer to buy all of the ordinary shares of the latter lapsed. The US life sciences company announced the acquisition of the Netherlands-based provider of molecular diagnostics and sample preparation technologies in March 2020 in a move to expand specialty […]